Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background: Continuous glucose monitoring (CGM), which studies have shown is beneficial for adults with type 1 diabetes, has not been well-evaluated in those with type 2 diabetes receiving insulin. Objective: To determine the effectiveness of CGM in adults with type 2 diabetes receiving multiple daily injections of insulin. Design: Randomized clinical trial. (The protocol also included a type 1 diabetes cohort in a parallel trial and subsequent second trial.) (ClinicalTrials.gov: NCT02282397). Setting: 25 endocrinology practices in North America. Patients: 158 adults who had had type 2 diabetes for a median of 17 years (interquartile range, 11 to 23 years). Participants were aged 35 to 79 years (mean, 60 years [SD, 10]), were receiving multiple daily injections of insulin, and had hemoglobin A1c (HbA1c) levels of 7.5% to 9.9% (mean, 8.5%). Intervention: Random assignment to CGM (n = 79) or usual care (control group, n = 79). Measurements: The primary outcome was HbA1c reduction at 24 weeks. Results: Mean HbA1c levels decreased to 7.7% in the CGM group and 8.0% in the control group at 24 weeks (adjusted difference in mean change, -0.3% [95% CI, -0.5% to 0.0%]; P = 0.022). The groups did not differ meaningfully in CGM-measured hypoglycemia or quality-of-life outcomes. The CGM group averaged 6.7 days (SD, 0.9) of CGM use per week. Limitation: 6-month follow-up. Conclusion: A high percentage of adults who received multiple daily insulin injections for type 2 diabetes used CGM on a daily or near-daily basis for 24 weeks and had improved glycemic control. Because few insulin-treated patients with type 2 diabetes currently use CGM, these results support an additional management method that may benefit these patients. Primary Funding Source: Dexcom.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Benefits of CGM in this population include reductions in A1C, fewer severe hypoglycemia events in children and adults, increased TIR, as well as significant reductions in hospitalizations for severe hypoglycemia and DKA.156,162–168”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [156]
In the citing paper
“The clinical efficacy of CGM has been demonstrated in numerous retrospective studies and RCTs of individuals with T1D regardless of insulin delivery method.156–161”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [156]
In the citing paper
“In addition, CGM use has been reported to reduce fear of hypoglycemia and increase confidence in avoiding/treating hypoglycemia.156,174,175”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [156]
In the citing paper
“A1C is currently recognized as the key surrogate marker for the development of longterm diabetes complications in people with type 1 and type 2 diabetes and has been used the primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [4]
In the citing paper
“Numerous studies have demonstrated significant clinical benefits of CGM use in people with diabetes regardless of insulin delivery method (1-15).”
From Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range (2019) · cites this paper as [4]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Assessing Psychosocial Distress in Diabetes
Polonsky, W. H., Fisher, L., Earles, J., Dudl, R. J., Lees, J., Mullan, J., & Jackson, R. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.626 · Cited by 1,575
Self-citationContinuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 3×
“org), was identical to that of a parallel trial in patients with type 1 diabetes (12), which also had a second phase assessing insulin pump initiation.”
BackgroundResultSelf-citationEffect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Self-citationClarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Self-citationHaak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541
Yeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Cited by
Items 201–300 of 636
Grunberger, G., Sze, D., Ermakova, A., Sieradzan, R., Oliveria, T., & Miller, E. M. (2020) · Clinical Diabetes · doi:10.2337/cd19-0008 · Cited by 28
Porter, M., Fonda, S. J., Swigert, T. J., & Ehrhardt, N. M. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211053886 · Cited by 28
Szmuilowicz, E. D., & Aleppo, G. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2110507 · Cited by 27
Eeg‐Olofsson, K., Svensson, A., Franzén, S., Ismail, H. A., Törnblom, M., & Levrat‐Guillen, F. (2023) · Diabetes and Vascular Disease Research · doi:10.1177/14791641211067418 · Cited by 39
Continuous glucose monitoring in persons with type 2 diabetes not using insulin
Cowart, K., Updike, W. H., & Franks, R. B. (2021) · Expert Review of Medical Devices · doi:10.1080/17434440.2021.1992274 · Cited by 30
Diabetes: the role of continuous glucose monitoring
Kluemper, J. R., Smith, A. C., & Wobeter, B. R. (2022) · Drugs in Context · doi:10.7573/dic.2021-9-13 · Cited by 33
Short-term use of CGM in youth onset type 2 diabetes is associated with behavioral modifications
Manfredo, J., Lin, T., Gupta, R., Abiola, K., West, M., Busin, K., Tracey, J., Brown, E. A., Magge, S. N., & Wolf, R. M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1182260 · Cited by 25
Kalyani, R. R., Allende-Vigo, M. Z., Antinori-Lent, K. J., Close, K. L., Das, S. R., Deroze, P., Edelman, S. V., El Sayed, N. A., Kerr, D., Neumiller, J. J., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad745 · Cited by 25
Gavin, J. R., & Bailey, C. J. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0211 · Cited by 29
Impact of Different Types of Data Loss on Optimal Continuous Glucose Monitoring Sampling Duration
Aktürk, H. K., Herrero, P., Oliver, N. S., Wise, H., Eikermann, E., Snell‐Bergeon, J. K., & Shah, V. N. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0093 · Cited by 25
Practical guidance for using the FreeStyle Libre flash continuous glucose monitoring in primary care
Unger, J., Kushner, P. R., & Anderson, J. E. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1744393 · Cited by 28
The Use of Continuous Glucose Monitoring to Diagnose Stage 2 Type 1 Diabetes
Mader, J. K., Wong, J. C., Freckmann, G., Garcia‐Tirado, J., Hirsch, I. B., Johnson, S. B., Kerr, D. E., Kim, S. H., Lal, R., Montaser, E., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251333441 · Cited by 31
Kruger, D. F., & Anderson, J. E. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0193 · Cited by 30
Self-citationUtilizing continuous glucose monitoring in primary care practice: What the numbers mean
Edelman, S. V., Cavaiola, T. S., BOEDER, S. C., & Pettus, J. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.10.013 · Cited by 27
Soriano, E. C., & Polonsky, W. H. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221094831 · Cited by 26
Self-citation2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea
Ko, S. (2021) · Journal of Korean Diabetes · doi:10.4093/jkd.2021.22.4.244 · Cited by 23
Peyyety, V., Zupa, M. F., Hewitt, B., Gonzalez, A. R., Mani, I., Prioleau, T., McCurley, J. L., Lin, Y. K., & Vajravelu, M. E. (2023) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106231205030 · Cited by 29
Wright, E. E., Roberts, G. J., Chuang, J. S., Nabutovsky, Y., Virdi, N., & Miller, E. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0015 · Cited by 22
Scalzo, P. (2021) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721721995478 · Cited by 22
Moser, O., Pandis, M., Aberer, F., Kojzar, H., Hochfellner, D. A., Elsayed, H., Motschnig, M., Augustin, T., Kreuzer, P., Pieber, T. R., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13598 · Cited by 25
Technological Advancements in the Management of Type 2 Diabetes
Grant, A. K., & Golden, L. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1278-3 · Cited by 28
Beyond A1C: exploring continuous glucose monitoring metrics in managing diabetes
Friedman, J. G., Coyne, K., Aleppo, G., & Szmuilowicz, E. D. (2023) · Endocrine Connections · doi:10.1530/ec-23-0085 · Cited by 22
Taylor, P. J., Thompson, C. H., Luscombe‐Marsh, N. D., Wycherley, T. P., Wittert, G., Brinkworth, G. D., & Zajac, I. T. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107814 · Cited by 24
How Significant Is Severe Hypoglycemia in Older Adults With Diabetes?
Chow, L. S., & Seaquist, E. R. (2020) · Diabetes Care · doi:10.2337/dci19-0069 · Cited by 21
Kompala, T., Wong, J. C., & Neinstein, A. B. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221088267 · Cited by 28
Assessment of the Glucose Management Indicator Using Different Sampling Durations
Bailey, R. J., Calhoun, P. M., Bergenstal, R. M., & Beck, R. W. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0284 · Cited by 22
Self-citationTime above range for predicting the development of type 2 diabetes
Marco, A., Pazos-Couselo, M., Moreno-Fernández, J., Díez‐Fernández, A., Alonso‐Sampedro, M., Fernández‐Merino, C., González‐Quintela, A., & Gudé, F. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1005513 · Cited by 25
The Evolution of Diabetes Technology – Options Toward Personalized Care
Zahid, M., Dowlatshahi, S., Kansara, A., & Sadhu, A. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.04.007 · Cited by 24
Garg, S., & Norman, G. J. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0656 · Cited by 24
Reed, J., Dong, T., Eaton, E., Friswold, J., Porges, J., Al‐Kindi, S. G., Rajagopalan, S., & Neeland, I. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15608 · Cited by 22
The Benefits Of Continuous Glucose Monitoring In Pregnancy
Yoo, J. H., & Kim, J. H. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1805 · Cited by 26
The use of technology in type 2 diabetes and prediabetes: a narrative review
Liarakos, A. L., Lim, J. Z. M., Leelarathna, L., & Wilmot, E. G. (2024) · Diabetologia · doi:10.1007/s00125-024-06203-7 · Cited by 27
Integrating Continuous Glucose Monitoring Into Clinical Practices and Patients' Lives
Hirsch, I. B., & Miller, E. M. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0233 · Cited by 24
Bosi, E., Gregori, G., Cruciani, G., Irace, C., Pozzilli, P., & Buzzetti, R. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109172 · Cited by 22
Miller, E. M., & Midyett, L. K. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0192 · Cited by 25
Grady, M., Cameron, H., Bhatiker, A., Holt, E., & Schnell, O. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0134 · Cited by 20
Peters, A. L., Ahmann, A., Hirsch, I. B., & Raymond, J. K. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00262 · Cited by 21
Self-citationKalantar, S. S., You, A. S., Norris, K. C., Nakata, T., Novoa, A., Juarez, K., Nguyen, D. V., & Rhee, C. M. (2019) · Kidney Medicine · doi:10.1016/j.xkme.2019.07.005 · Cited by 19
Evolving Use of Continuous Glucose Monitoring Beyond Intensive Insulin Treatment
Wright, E. E., & Subramanian, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0191 · Cited by 20
Rizos, E. C., Markozannes, G., Charitakis, N., Filis, P., Stoimeni, A. E., Nørgaard, K., Ntzani, E. E., & Tsilidis, K. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0599 · Cited by 21
Rose, L., Klausmann, G., & Seibold, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00978-9 · Cited by 18
Divani, M., Georgianos, P. I., Didangelos, T., Liakopoulos, V., Makedou, K., Iliadis, F. S., Savopoulos, C. G., & Grekas, D. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184116 · Cited by 20
Fritschi, C., Kim, M. J., Srimoragot, M., Jun, J., Sanchez, L. E., & Sharp, L. K. (2022) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106221076042 · Cited by 18
Roadmap to the Effective Use of Continuous Glucose Monitoring in Primary Care
Martens, T. W. (2023) · Diabetes Spectrum · doi:10.2337/dsi23-0001 · Cited by 20
Hannah, K. L., Nemlekar, P. M., Green, C. R., & Norman, G. J. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02851-8 · Cited by 19
Lever, C. S., Williman, J. A., Boucsein, A., Watson, A. S., Sampson, R. S., Sergel‐Stringer, O. T., Keesing, C., Chepulis, L. M., Wheeler, B. J., de Bock, M. I., et al. (2024) · Diabetic Medicine · doi:10.1111/dme.15348 · Cited by 20
Pleus, S., Heinemann, L., & Freckmann, G. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817753629 · Cited by 18
Angellotti, E., Muppavarapu, S., Siegel, R. D., & Pittas, A. G. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0405 · Cited by 21
Insulin Pump Therapy and Continuous Glucose Monitoring
Schütz-Fuhrmann, I., Rami-Merhar, B. M., Fröhlich-Reiterer, E. E., Hofer, S. E., Tauschmann, M., Mader, J. K., Resl, M., Kautzky‐Willer, A., Winhofer-Stöckl, Y., Laimer, M., et al. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780199568604.001.0001 · Cited by 19
Sherrill, C. H., Lee, S., & Bradley, C. L. (2021) · Currents in Pharmacy Teaching and Learning · doi:10.1016/j.cptl.2021.11.021 · Cited by 20
Modzelewski, K. L., Murati, J., Charoenngam, N., Rehm, C., & Steenkamp, D. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0557 · Cited by 19
Alshannaq, H. A., Isitt, J. J., Pollock, R. F., Norman, G. J., Cogswell, G., Lynch, P. M., & Roze, S. (2023) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2023-0075 · Cited by 21
Hannah, K. L., Nemlekar, P. M., Johnson, M. L., Cherñavvsky, D. R., & Norman, G. J. (2024) · Kidney360 · doi:10.34067/kid.0000000000000396 · Cited by 17
Schliess, F., Heise, T., Benesch, C., Mianowska, B., Stegbauer, C., Broge, B., Gillard, P., Binkley, G., Crône, V., Carlier, S., et al. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818803588 · Cited by 17
Glycemic Status Assessment by the Latest Glucose Monitoring Technologies
Malandrucco, I., Russo, B., Picconi, F., Menduni, M., & Frontoni, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218243 · Cited by 17
Galindo, R. J., Aleppo, G., Parkin, C. G., Baidal, D. A., Carlson, A. L., Cengiz, E., Forlenza, G. P., Kruger, D. F., Levy, C. J., McGill, J. B., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221144052 · Cited by 19
Self-citationFirst real-world experience with bigfoot unity: a 6-month retrospective analysis
Baliga, B. S., Tillman, J. B., Olson, B., Vaughan, S., Sheikh, F. N., & Malone, J. K. (2023) · Clinical Diabetes · doi:10.2337/cd22-0126 · Cited by 15
“but given other studies’ findings that most people using an MDI insulin regimen take three rapid-acting injections per day (19), our findings of an average of 2.”
ResultContinuous Glucose Monitoring Frequency and Glycemic Control in People With Type 2 Diabetes
Hirsch, I. B., Garg, S. K., Repetto, E., Snell‐Bergeon, J. K., Ulmer, B. J., Perkins, C., & Bergenstal, R. M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.39278 · Cited by 19
Self-citationMiller, E. M., & Miller, K. (2024) · Clinical Diabetes · doi:10.2337/cd23-0077 · Cited by 18
den Braber, N., Vollenbroek-Hutten, M. M. R., Westerik, K. M., Bakker, S. J. L., Navis, G. J., van Beijnum, B.-J. F., & Laverman, G. D. (2021) · Diabetes Care · doi:10.2337/dc20-2241 · Cited by 21
Sergel-Stringer, O. T., Wheeler, B. J., Styles, S. E., Boucsein, A., Lever, C. S., Paul, R. G., Sampson, R., Watson, A., & de Bock, M. I. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01403-9 · Cited by 15
Alva, S., Bhargava, A., Bode, B. W., Brazg, R., CASTORINO, K. N., Kipnes, M. S., Liljenquist, D. R., Tran, H., Liu, H., & Nada, M. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251329364 · Cited by 23
Agarwal, S., Varghese, R. T., SAVIAN, R. E. N. A. T. O. R. E. Z. E. N. D. E., Wang, C. C. L., & Galindo, R. J. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.05.749 · Cited by 15
Combining CGM and an Online Peer Support Community for Hispanic Adults with T2D: A Feasibility Study
Litchman, M. L., Ng, A., Sanchez-Birkhead, A., Allen, N. A., Gonzales, B. R., Iacob, E., & Greenwood, D. A. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211032278 · Cited by 17
Karter, A. J., Parker, M. M., Moffet, H. H., Gilliam, L. K., & Dlott, R. S. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0450 · Cited by 15
Discordance between postprandial plasma glucose measurement and continuous glucose monitoring
Barua, S., Wierzchowska-McNew, R. A., Deutz, N. E. P., & Sabharwal, A. (2022) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac181 · Cited by 17
Psavko, S., Katz, N., Mirchi, T., & Green, C. R. (2022) · JMIR Human Factors · doi:10.2196/42057 · Cited by 15
BOEDER, S. C., Matamoros, D., & Mansy, C. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01330-z · Cited by 16
Patient‐reported outcomes in studies of diabetes technology: What matters
Liarakos, A. L., Crabtree, T. S. J., & Wilmot, E. G. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15858 · Cited by 19
Advances in diabetes technology within the digital diabetes ecosystem
Aktürk, H. K., & Bindal, A. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.10-b.s7 · Cited by 22
Bergenstal, R. M., Johnson, M. L., Aroda, V. R., Brazg, R., Dreon, D. M., Frías, J. P., Kruger, D. F., Molitch, M. E., Mullen, D. M., Peyrot, M. F., et al. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211016513 · Cited by 15
Self-citationHow use of continuous glucose monitoring can address therapeutic inertia in primary care
Martens, T. W., & Parkin, C. G. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2080419 · Cited by 16
Emerging technologies for the management of type 2 diabetes mellitus
Shah, N. A., & Levy, C. J. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13188 · Cited by 18
Norman, G. J., Fernandes, J., Nemlekar, P. M., Andrade, S. B., Lupton, L. L., & Berk, A. R. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.24255 · Cited by 21
Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients
Franck, A. J., Hendrickson, A. L., Telford, E. D., Davids, B. L., Casanova, I. M., Rosen, A. N., Hadigal, S., & Ross, R. C. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.02.006 · Cited by 15
Real-World Diabetes Technology: Overcoming Barriers and Disparities
Messer, L. H., Addala, A., & WEINZIMER, S. A. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.2511 · Cited by 15
Nemlekar, P. M., Hannah, K. L., Green, C. R., & Norman, G. J. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01529-8 · Cited by 14
Patel, D. K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13224 · Cited by 14
Narasaki, Y., Park, E., You, A. S., Daza, A. C., Peralta, R. A., Guerrero, Y., Novoa, A., Amin, A., Nguyen, D. V., Price, D. A., et al. (2021) · Seminars in Dialysis · doi:10.1111/sdi.13009 · Cited by 15
Self-citationUse of continuous glucose monitoring trend arrows in the younger population with type 1 diabetes
Elbarbary, N. S., Moser, O., Al-Yaarubi, S., Alsaffar, H., Shaikh, A. M. A., Ajjan, R., & Deeb, A. (2021) · Diabetes and Vascular Disease Research · doi:10.1177/14791641211062155 · Cited by 16
Role of Continuous Glucose Monitoring in Insulin-Requiring Patients with Diabetes
Welsh, J. B. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0100 · Cited by 17
Puhr, S., Calhoun, P. M., Welsh, J. B., & Walker, T. C. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0134 · Cited by 17
Lanzinger, S., Best, F., Bergmann, T., Laimer, M., Lipovsky, B., Danne, T., Zimny, S., Bramlage, P., Meyhöfer, S., & Holl, R. W. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0063 · Cited by 13
Engler, S., Fields, S. A., Leach, W., & Loon, M. V. (2022) · Journal of Technology in Behavioral Science · doi:10.1007/s41347-022-00247-5 · Cited by 15
Making sense of glucose sensors in end-stage kidney disease: A review
Williams, M. E., Steenkamp, D., & Wolpert, H. A. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.1025328 · Cited by 14
Diabetes Technology in People with Type 2 Diabetes: Novel Indications
Agarwal, S., Galindo, R. J., Shah, A. V., & Abreu, M. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01536-4 · Cited by 14
Petry, S. F., Bienhaus, M., Petry, F. W., Pétry, J., Heinemann, L., & Gäth, S. A. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241305161 · Cited by 14
Kazemi, A. H., Wang, W., Wang, Y., Khodaie, F., & Rezaeizadeh, H. (2019) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2019.02.003 · Cited by 21
Martens, T. W., Bergenstal, R. M., Pearson, T. L., Carlson, A. L., Scheiner, G., Carlos, C., Liao, B., Syring, K. E., & Pollom, R. D. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1851946 · Cited by 14
Self-citationDowd, R., Jepson, L. H., Green, C. R., Norman, G. J., Thomas, R., & Leone, K. (2023) · JMIR Diabetes · doi:10.2196/43991 · Cited by 14
Glycemic Risk Index Profiles and Predictors Among Diverse Adults With Type 1 Diabetes
Hoogendoorn, C. J., Hernandez, R., Schneider, S., Harmel, M., Pham, L. T., Crespo-Ramos, G., Agarwal, S., Crandall, J. P., Peters, A. L., Spruijt‐Metz, D., et al. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231164151 · Cited by 13
CASTORINO, K. N., Durnwald, C. P., Ehrenberg, S., Ehrhardt, N. M., Isaacs, D., Levy, C. J., Valent, A. M., & Continuous Glucose Monitoring for Gestational Diabetes Management Working Group (2024) · Journal of Women s Health · doi:10.1089/jwh.2023.0864 · Cited by 15
Kent, D. M., Nelson, J., Pittas, A. G., Colangelo, F. R., Koenig, C., Klaveren, D. V., Ciemins, E. L., & Cuddeback, J. K. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.09.012 · Cited by 12
Alshannaq, H. A., Pollock, R. F., Joubert, M., Ahmed, W., Norman, G. J., Lynch, P. M., & Roze, S. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2023-0174 · Cited by 14
Zhang, L., Sun, X., & Tian, Q. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02241-0 · Cited by 12
Accuracy of the 15.5-Day G7 iCGM in Adults with Diabetes
Garg, S. K., Bailey, T. S., CASTORINO, K. N., Christiansen, M. P., Liljenquist, D. R., Salazar, H., Aktürk, H. K., Gao, S. X., Johnson, M. L., & Beck, S. E. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0139 · Cited by 13
Continuous glucose monitoring to assess glucose variability in type 3c diabetes
Lee, V. T. Y., Poynten, A. M., & Depczynski, B. (2022) · Diabetic Medicine · doi:10.1111/dme.14882 · Cited by 17
Farhan, H., Bukhari, K., Grewal, N., Devarasetty, S., & Munir, K. M. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-248579 · Cited by 15
Senior, P. A. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.09.001 · Cited by 12
Continuous Glucose Monitoring for Type 2 Diabetes: How Does It Compare with Type 1 Diabetes?
Beck, R. W., & Bergenstal, R. M. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0374 · Cited by 12
Self-citation
Metadata
- Authors
- Beck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., Aronson, R., Toschi, E., Kollman, C., Bergenstal, R., & for the DIAMOND Study Group*
- Affiliations
- Joslin Diabetes Center (US)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-09-19
- Volume
- 167
- Issue
- 6
- Pages
- 365-374
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2753830550
- Semantic Scholar
- 4f35ac21c54271e1101cc587d928e543765ee06a
- Cited by
- 635
- References
- 31
- Citations by year
- 2026: 58 · 2025: 91 · 2024: 95 · 2023: 77 · 2022: 77 · 2021: 85 · 2020: 43 · 2019: 56 · 2018: 46 · 2017: 6
- FWCI
- 32.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- continuous glucose monitoring, type 2 diabetes, multiple daily insulin injections, glycemic control, HbA1c reduction, hypoglycemia, quality of life, usual care, type 1 diabetes
- MeSH terms
- Adult, Aged, Bacterial Proteins, Diabetes Mellitus, Type 2, Drug Administration Schedule, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Membrane Proteins, Middle Aged, Quality of Life, Blood Glucose Self-Monitoring, Patient Satisfaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.